- The study aimed to explore if starting vedolizumab (a medication for inflammatory bowel disease) was linked to new-onset spondyloarthritis (SpA) in patients with IBD through clinical evaluations and MRIs.
- 24 patients with active ulcerative colitis or Crohn's disease participated, with assessments made before starting treatment and at 8 and 24 weeks.
- Results showed that none of the patients developed new forms of axial or peripheral SpA after 24 weeks, indicating that vedolizumab does not appear to trigger these conditions in either TNF inhibitor-naïve or experienced patients.